newsfilter
← Latest News
Business Wire·

Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021

– Nedosiran Achieved Primary Endpoint Demonstrating Statistically Significant Sustained Reduction in Urinary Oxalate Excretion and Showed Robust Efficacy in PH1 – – Real-World Healthcare Utilization Data Showed Delayed Diagnosis in More Than